MedTrace Logo

Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort

NCT03111966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2019-02-11

No results posted yet for this study

Summary

This is a multicentre, descriptive, observational and ambispective study carried out in patients who are treated with Elbasvir/Grazoprevir in hospitals that included their data in Hepa-C Registry (directed by the Spanish Association for the Study of the Liver and the Networked Biomedical Research Centre for Hepatic and Digestive Diseases).

Conditions

  • Hepatitis C

Interventions

OTHER

Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir

Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir

Sponsors & Collaborators

  • Hepa C

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2017-04-30
Completion
2017-11-30
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03111966 on ClinicalTrials.gov